Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive [Phase 1, Phase 2]
Phase 1/2 trial update on a T cell receptor therapy targeting MAGE-A3 in HLA-DP0401 positive metastatic cancer; study completed with posted …
-
CLINICAL_TRIALS trial_result · 2022-03-22Clinical Trial Update: Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma [Phase 2]
Phase 2 trial results evaluating adjuvant nivolumab with low-dose ipilimumab in stage III melanoma and resected stage IV melanoma have been …
-
FDA approval · 2022-03-18FDA Approved: OPDUALAG — Original Application (E.R. Squibb & Sons, L.L.C.)
FDA approved Opdualag (nivolumab and relatlimab-rmbw) based on the original application for unresectable or metastatic melanoma.
-
CLINICAL_TRIALS trial_result · 2022-03-18Clinical Trial Update: Safety and Efficacy of DCB-BO1301 in Advanced Melanoma [Phase 1, Phase 2]
A clinical trial update reports safety and efficacy data for DCB-BO1301 in advanced melanoma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2022-03-10Clinical Trial Update: Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut [Phase 2]
Phase 2 trial evaluating imatinib with toripalimab in CKIT-mutant locally advanced or metastatic melanoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-02-24Clinical Trial Update: Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation [Phase 1, Phase 2]
Phase 1/2 trial evaluating vemurafenib plus cobimetinib plus PEG-interferon in advanced melanoma with BRAF V600 mutation completed.
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma [Phase 2]
A Phase 2 study evaluating metabolomic and inflammatory effects of oral aspirin in individuals at risk for melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma [Phase 2]
Phase 2 trial assessing aspirin as a UV protectant in humans at risk for melanoma has completed.
-
FDA approval · 2022-02-11FDA Approved: BRAFTOVI — Supplemental Application (Array BioPharma Inc.)
The FDA approved a supplemental application for BRAFTOVI (encorafenib) submitted by Array BioPharma Inc. The specific nature of the suppleme…
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma [Phase 2]
Phase II study of Abraxane (paclitaxel albumin-bound) plus ipilimumab in metastatic melanoma completed; results posted.
-
CLINICAL_TRIALS trial_result · 2022-02-03Clinical Trial Update: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma [Phase 2]
Phase 2 clinical trial evaluating vemurafenib in combination with lymphodepletion, adoptive cell transfer, and high-dose IL-2 for metastatic…
-
CLINICAL_TRIALS trial_result · 2022-01-20Clinical Trial Update: Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma [Phase 1, Phase 2]
Phase 1/2 trial investigating dabrafenib, trametinib, and hydroxychloroquine in advanced BRAF-mutant melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-12-13Clinical Trial Update: A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors [Phase 1]
A Phase 1 dose-escalation study of PF-06801591 in multiple solid tumors including melanoma, head and neck cancer, ovarian cancer, sarcoma, n…
-
CLINICAL_TRIALS trial_result · 2021-12-09Clinical Trial Update: Intratumoral Injections of LL37 for Melanoma [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial evaluating intratumoral injections of LL37 for melanoma has completed with posted results.
-
FDA label_change · 2021-12-03FDA Approved: MEKINIST — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for MEKINIST (trametinib) from Novartis Pharmaceuticals Corporation. This action updates the dru…
-
CLINICAL_TRIALS trial_result · 2021-12-02Clinical Trial Update: To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. [Phase 2]
Phase 2 trial evaluating whether continuing vemurafenib+cobimetinib with local treatment improves efficacy beyond progression versus second-…
-
CLINICAL_TRIALS trial_result · 2021-12-01Clinical Trial Update: PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors [Phase 2]
Phase 2 study of the PD-L1 Probody therapeutic CX-072 in combination with other anticancer therapy in adults with solid tumors, including un…
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access [NA]
Clinical trial update on targeted melanoma detection using skin self-examination during COVID-19 restrictions, with completed status and pos…
-
CLINICAL_TRIALS trial_result · 2021-11-22Clinical Trial Update: A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients [Phase 1, Phase 2]
Phase I/II open-label study of ipilimumab with GM-CSF in unresectable metastatic melanoma shows completed status with posted results.
-
CLINICAL_TRIALS trial_result · 2021-11-16Clinical Trial Update: A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma [Phase 2]
Phase 2 trial evaluating CDX-1401 vaccine with or without CDX-301 for various-stage melanoma has completed enrollment with results posted.
-
CLINICAL_TRIALS trial_result · 2021-11-11Clinical Trial Update: Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors [Phase 1, Phase 2]
Clinical trial update on CAR-T therapy for intermediate and advanced tumors, including melanoma and non-small cell lung cancer, across Phase…
-
CLINICAL_TRIALS trial_result · 2021-11-04Clinical Trial Update: Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma [Phase 2]
Phase 2 clinical trial update evaluating sitravatinib with or without tislelizumab in unresectable or metastatic melanoma.
-
CLINICAL_TRIALS trial_result · 2021-10-29Clinical Trial Update: Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients [Phase 2]
Phase 2 trial update evaluating adjuvant interleukin-2 (Proleukin) combined with dacarbazine (DTIC) in high-risk metastatic melanoma patient…
-
CLINICAL_TRIALS trial_result · 2021-10-28Clinical Trial Update: Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma [Phase 2]
Phase 2 clinical trial update for perioperative encobini in BRAFV600-mutant melanoma with stage III/oligometastatic stage IV disease; curren…
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: Fibrin Melanoma Axillary Node Study in Patients With Melanoma [NA]
Completed clinical trial evaluating fibrin-focused intervention in melanoma; results posted.